Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
Walgreens Boots Alliance, Inc. became a privately owned company after Sycamore Partners completed its acquisition of WBA in August 2025. News about the former public issuer centers on the transition of Walgreens and related businesses under private ownership, including Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD.
Recurring company updates also cover Walgreens' U.S. retail pharmacy and health-services operations, specialty pharmacy limited-distribution drug relationships, and capital actions tied to WBA and Walgreen Co. senior notes, including tender offers and consent solicitations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Walgreens has released the COVID-19 Pulse Check study, surveying over 1,000 seniors aged 55 and older in the U.S. The findings reveal that 42% of seniors are less socially active than pre-pandemic levels, with 20% feeling lonelier. Key concerns include a significant worry about socializing safely, particularly among the Black senior community, where 39% report feeling socially isolated. The report indicates that 70% of seniors feel more confident socializing around vaccinated individuals. Walgreens is promoting Seniors Day discounts and offering services like at-home COVID-19 tests and vaccination support during these events to help seniors regain confidence in social interactions.
Walgreens Boots Alliance (WBA) has announced a quarterly dividend of 48 cents per share, maintaining the same amount as the previous quarter and reflecting a 0.5% increase from last year. This dividend is scheduled to be paid on June 12, 2023, to stockholders recorded by May 19, 2023. WBA has a strong dividend history, having paid dividends for 362 consecutive quarters and raised them for 47 consecutive years. The company operates approximately 13,000 locations across the U.S., Europe, and Latin America, employing over 325,000 people and playing a significant role in the healthcare ecosystem. WBA is also recognized for its sustainability efforts and is part of the Dow Jones Sustainability Indices.
Walgreens and Prothena have announced a collaboration to enhance patient recruitment for Prothena's PRX012, a potential Alzheimer’s treatment currently in the ASCENT-2 clinical trial. Walgreens will utilize its extensive network and healthcare capabilities to identify suitable candidates, focusing on underserved communities. This trial has received Fast Track designation from the FDA, indicating its potential significance in addressing Alzheimer’s disease, which affects over 6.5 million Americans aged 65 and older. The partnership aims to create a more diverse patient population for the trial, aligning with the ENACT Act to improve inclusivity in Alzheimer’s research. Key topline data from ongoing Phase 1 studies is expected by the end of 2023.
Walgreens has launched the ninth annual Red Nose Day campaign, promoting in-store sales and donations to combat child poverty. From now until May 31, customers can donate via pin-pad or purchase a Red Nose for $1, with all proceeds aiding the cause. Following a record-breaking year in 2022, Walgreens contributed over $38 million to this initiative. Since 2015, Walgreens has raised more than $178 million, impacting over 31 million children globally. The funds support various charities focused on ensuring children's access to health, education, and well-being. Walgreens reaffirms its commitment to improving community health as it engages in this charitable effort for a healthier future.